Rhythm Tops Q3 Revenue Estimates, Lands $750M Term Loan, and Maps Bivamelagon Phase 3
RYTM sits 20% above its 52-week low of $74.5 on elevated volume (3.0× avg).
Summary
Rhythm posted Q3 revenue of $92.1 million, up 29% sequentially, and disclosed a new $750 million five-year term loan alongside a restructured LG Chem royalty deal as bivamelagon advances into Phase 3.
Key Events · Earnings and Guidance · RYTM
-
Q3 Revenue Jumps 29% Sequentially
Net product revenue from IMCIVREE reached $92.1 million, up from $71.3 million in Q2 2026. U.S. revenue accounted for $67.5 million, or 73% of the total, with ex-U.S. revenue at $24.7 million.
-
$750M Term Loan Secured
The five-year facility, led by KKR's HealthCare Royalty with Blackstone Life Sciences, carries SOFR+4.60% (1.00% floor), 1.0% OID and no amortization. Its $250 million initial draw lifts pro-forma cash to about $570.9 million ($320.9M + $250M).
-
LG Chem Royalty Restructured
To cut the MC4R portfolio royalty to 1%, Rhythm will pay $350 million over four years: $70 million within 15 business days, then $100 million in September 2027, $100 million in September 2028 and $80 million in September 2029.
-
Bivamelagon Heads to Phase 3
Pivotal trials are planned in acquired hypothalamic obesity (52 weeks, BMI reduction endpoint) and Prader-Willi syndrome (26 weeks, hyperphagia endpoint), with the acquired-HO trial starting by year-end 2026.
Analysis · RYTM · Life Sciences
The quarter's $92.1 million in revenue beat the prior quarter by 29%, as the U.S. acquired-HO launch scaled past 700 start forms. More important for the balance sheet, a new $750 million five-year term loan led by KKR's HealthCare Royalty with Blackstone provides a $250 million initial draw that lifts pro-forma cash to roughly $570.9 million ($320.9M + $250M), removing near-term financing risk. Cost is the trade-off: the LG Chem amendment swaps a low-to-mid-single-digit royalty for a 1% royalty by paying $350 million over four years, including $70 million within 15 business days, while the loan carries SOFR+4.60% with a 1.00% floor. Next value driver is bivamelagon's move into Phase 3 in both acquired HO and Prader-Willi syndrome, with the acquired-HO trial starting by year-end 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RYTM was trading at $89.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $74.50 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.